<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02132754</url>
  </required_header>
  <id_info>
    <org_study_id>4166-001</org_study_id>
    <secondary_id>MK-4166-001</secondary_id>
    <nct_id>NCT02132754</nct_id>
  </id_info>
  <brief_title>Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)</brief_title>
  <official_title>Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination With Pembrolizumab in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is planned to be a 5-part dose-escalation study to determine the safety and tolerability
      of MK-4166 monotherapy and MK-4166 plus pembrolizumab combination therapy and to establish
      the maximum tolerated dose (MTD) or maximum administered dose (MAD) of MK-4166 and MK-4166
      plus pembrolizumab in participants with advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part A, MK-4166 doses will be escalated quickly in successive cohorts and based on safety
      events may progress to Part B, in which the preliminary MTD will be identified. Based on
      safety events the study may progress to Part C in which the MTD will be confirmed. In Part D,
      participants will receive escalating doses of MK-4166 plus a fixed dose of pembrolizumab
      (MK-3475) 200 mg to determine the MTD for MK-4166 in combination with pembrolizumab. Based on
      safety events in Part D, the study may progress to Part E in which the MTD for MK-4166 in
      combination with pembrolizumab will be confirmed.

      With Amendments 05/06, the dose confirmation Part C will be removed and the dose confirmation
      Part E (combination of MK-4166 and pembrolizumab) will be limited to participants with
      advanced malignant melanoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2014</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities (DLTs) with MK-4166 and with MK-4166+Pembrolizumab</measure>
    <time_frame>Cycle 1 (up to 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing adverse events (AEs)</measure>
    <time_frame>From first dose up to 30 days post last dose (up to 25 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study drug due to AEs</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <number_of_arms>34</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>MK-4166 0.0015 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received 0.0015 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 0.0045 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received 0.0045 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 0.014 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received 0.014 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 0.04 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received 0.04 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 0.12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received 0.12 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 0.37 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received 0.37 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 1.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 3.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 42 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 59 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 82 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 170 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 240 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 340 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 480 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 670 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 1.1 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 3.3 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 10 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 30 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 42 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 59 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 82 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 120 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 170 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 240 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 340 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 480 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 670 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4166 900 mg + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-4166</intervention_name>
    <arm_group_label>MK-4166 0.0015 mg</arm_group_label>
    <arm_group_label>MK-4166 0.0045 mg</arm_group_label>
    <arm_group_label>MK-4166 0.014 mg</arm_group_label>
    <arm_group_label>MK-4166 0.04 mg</arm_group_label>
    <arm_group_label>MK-4166 0.12 mg</arm_group_label>
    <arm_group_label>MK-4166 0.37 mg</arm_group_label>
    <arm_group_label>MK-4166 1.1 mg</arm_group_label>
    <arm_group_label>MK-4166 1.1 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 10 mg</arm_group_label>
    <arm_group_label>MK-4166 10 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 120 mg</arm_group_label>
    <arm_group_label>MK-4166 120 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 170 mg</arm_group_label>
    <arm_group_label>MK-4166 170 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 240 mg</arm_group_label>
    <arm_group_label>MK-4166 240 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 3.3 mg</arm_group_label>
    <arm_group_label>MK-4166 3.3 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 30 mg</arm_group_label>
    <arm_group_label>MK-4166 30 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 340 mg</arm_group_label>
    <arm_group_label>MK-4166 340 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 42 mg</arm_group_label>
    <arm_group_label>MK-4166 42 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 480 mg</arm_group_label>
    <arm_group_label>MK-4166 480 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 59 mg</arm_group_label>
    <arm_group_label>MK-4166 59 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 670 mg</arm_group_label>
    <arm_group_label>MK-4166 670 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 82 mg</arm_group_label>
    <arm_group_label>MK-4166 82 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 900 mg</arm_group_label>
    <arm_group_label>MK-4166 900 mg + Pembro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>MK-4166 1.1 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 10 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 120 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 170 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 240 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 3.3 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 30 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 340 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 42 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 480 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 59 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 670 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 82 mg + Pembro</arm_group_label>
    <arm_group_label>MK-4166 900 mg + Pembro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Has a histologically- or cytologically-confirmed metastatic solid tumor for which
             there is no available therapy which may convey clinical benefit. Part E: Has advanced
             malignant melanoma.

          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version
             1.1

          -  Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale

          -  Adequate organ function

          -  Female participants of childbearing potential must have a negative urine or serum
             pregnancy test and must be surgically sterile or willing to use 2 methods of birth
             control or abstain from heterosexual activity for the course of the study through 120
             days after last dose of study drug

          -  Male participants must agree to use an adequate method of contraception during sexual
             contact with females of childbearing potential starting with the first dose of study
             drug through 180 days after the last dose of study drug

          -  Submit an evaluable tumor sample for analysis.

        Exclusion criteria:

          -  Chemotherapy, radiation, or biological cancer therapy within 4 weeks prior to the
             first dose of study drug, or who has not recovered to Common Terminology Criteria for
             Adverse Events (CTCAE) Grade 1 or better from the adverse events due to cancer
             therapeutics administered more than 4 weeks earlier

          -  Currently participating or has participated in a study of an investigational agent or
             using an investigational device within 28 days of administration of MK-4166

          -  Expected to require any other form of antineoplastic therapy while on study

          -  On chronic systemic steroid therapy in excess of replacement doses, or on any other
             form of immunosuppressive medication

          -  History of a malignancy for which potentially curative treatment has been completed,
             with no evidence of malignancy for 5 years excepting successful definitive resection
             of basal cell carcinoma of the skin, superficial bladder cancer, or in situ cervical
             cancer

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  Severe hypersensitivity reaction to treatment with another monoclonal antibody

          -  Active autoimmune disease or a documented history of autoimmune disease, except
             vitiligo or resolved childhood asthma/atopy

          -  Active infection requiring therapy

          -  Current pneumonitis, or a history of (non-infectious) pneumonitis that required
             steroids

          -  Prior stem cell or bone marrow transplant

          -  Positive for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C

          -  Known psychiatric or substance abuse disorders that would interfere with cooperation
             with the requirements of the trial

          -  Regular user (including &quot;recreational use&quot;) of any illicit drugs or recent history
             (within the last year) of substance abuse (including alcohol)

          -  Symptomatic ascites or pleural effusion

          -  Pregnant, breastfeeding, or expecting to conceive or father children within the
             projected duration of the study

          -  Clinically significant heart disease

          -  Major surgery in the past 16 weeks

          -  Received a live vaccine within 30 days prior to first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>July 13, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

